SCHEMBL3016091

SCHEMBL3016091

Cc1ccccc1Cc1csc(N2CCN(S(=O)(=O)c3cccc(Cl)c3)CC2)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.48
LMNA P02545 4/20 0.48
GBA1 P04062 2/20 0.45
TDP1 Q9NUW8 1/20 0.45
KMT2A Q03164 5/20 0.45
ALDH1A1 P00352 5/20 0.45
MEN1 O00255 4/20 0.45
CHRM4 P08173 1/20 0.44
LPAR2 Q9HBW0 1/20 0.43
HTT P42858 4/20 0.43
GAA P10253 2/20 0.43
POLB P06746 1/20 0.43
MAPT P10636 1/20 0.43
NPSR1 Q6W5P4 2/20 0.42
HSD11B1 P28845 1/20 0.42
KDM4E B2RXH2 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
PKM P14618 1/20 0.41
PIK3CA P42336 1/20 0.41
MTOR P42345 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3016087 0.94 LMNA (0.47) TSHRLMNAGBA1TDP1KMT2A
SCHEMBL3014631 0.92 GBA1 (0.44) TSHRLMNAGBA1TDP1KMT2A
SCHEMBL3021257 0.91 LMNA (0.48) TSHRLMNAGBA1KMT2AALDH1A1
SCHEMBL3009189 0.90 TSHR (0.47) TSHRLMNAGBA1TDP1KMT2A
SCHEMBL3016682 0.90 NPSR1 (0.48) TSHRLMNAGBA1TDP1KMT2A
SCHEMBL3008465 0.90 SMN1; SMN2 (0.49) TSHRLMNATDP1KMT2AALDH1A1
SCHEMBL3019294 0.89 TSHR (0.50) TSHRLMNATDP1KMT2AALDH1A1
SCHEMBL3016995 0.89 KMT2A (0.47) TSHRLMNAGBA1TDP1KMT2A
SCHEMBL3012549 0.89 GBA1 (0.45) TSHRLMNAGBA1TDP1KMT2A
SCHEMBL3017845 0.88 ALDH1A1 (0.48) TSHRLMNAGBA1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA TSHR 3320/4885LMNA 80/4885GBA1 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.